What Streptokinase Treats: Main Uses and Benefits

Streptokinase is used primarily to help dissolve acute, dangerous blood clots across several key therapeutic areas. The medication is applied in the management of acute thrombotic events where prompt lysis (dissolution) of the clot is commonly needed. This supports the general therapeutic benefit of restoring blocked circulation in acute clinical scenarios.

It is commonly used to help manage conditions characterized by periods of heightened symptoms and severe physiological strain, including acute myocardial infarction (heart attack), massive pulmonary embolism, and extensive deep vein thrombosis.

“The primary goal of this therapy is to support the patient during difficult episodes by easing acute distress and contributing to the stability of the circulatory system.”

Targeting Acute Thrombotic Events

The therapy is relevant for easing symptoms related to organ-specific functional stress and systemic imbalance. In myocardial infarction (STEMI), the primary therapeutic benefit involves supporting the restoration of blood flow (reperfusion), which may assist with managing the extent of heart muscle damage and may help support overall patient stability. For massive pulmonary embolism, it assists with easing the acute distress and contributes to easing distress related to blood pressure changes. The medication is also applied to address acute blockages in peripheral arteries and is also used to help address symptoms that interfere with daily functioning by restoring the patency of essential vascular access cannulae or shunts.

Quick Fact: Relief for Acute Ischemia
Supports the rapid restoration of blood flow (reperfusion) to oxygen-starved tissue, which may assist with managing the severity of the acute episode.

Eligibility Map: Who Can and Cannot Use Streptokinase

This map summarizes the official population eligibility and non-eligibility criteria for Streptokinase, strictly based on government regulatory documentation.

Category	Official Regulatory Status
Populations for whom use is allowed	Adults with objectively diagnosed thrombotic events.
Populations for whom use is contraindicated	Patients with active internal bleeding or uncontrolled clotting disorders. Prohibited in individuals with recent (within 2 months) stroke or intracranial neoplasm. Use is contraindicated during pregnancy and after recent childbirth (parturition).
Age-related eligibility rules	Pediatric use is not established as safety and efficacy studies have not been performed. Information on use in geriatric patients is often noted as not fully available.
Eligibility-related restrictions	Use is not recommended for patients who have received Streptokinase within the previous 12 months due to the likelihood of neutralizing antibodies. Use requires caution in patients with severe hepatic or renal disease. Safety during breastfeeding is not established.

---

Connection to the Overall Eligibility Profile

Official regulatory documents define eligibility for Streptokinase primarily by the need to manage the risk of severe hemorrhage, which determines absolute contraindications. Eligibility is further constrained by the potential for antibody formation from prior exposure and by the regulatory status of certain populations, such as pediatric and pregnant groups, where safety has not been established or is prohibited. These criteria dictate precisely who may or may not be administered the medicine.

Interactions with other medicines and products — official regulatory information for Streptokinase

Interaction Scope

Element	Description
Medicinal product categories with documented interactions:	Anticoagulants, Antiplatelet Agents, Other Thrombolytics, Antifibrinolytic Agents, and specific herbal products.
Mechanistic basis of interactions (only if stated in label):	Pharmacodynamic potentiation (additive effect on hemostasis); Pharmacodynamic reversal (inhibition of Streptokinase effects).
Timing-based interaction rules (if applicable):	Re-administration is restricted to a period greater than 12 months from prior therapy.
Interaction-related restrictions:	Administration is contraindicated if the patient received Streptokinase within the window of 5 days to 12 months previously.

Interaction Classifications (High-Level)

Classification	Description
Interaction severity classification:	Contraindicated Combination (Previous Exposure); Clinically Significant Interaction (Increased Hemorrhage Risk); Inhibitory Interaction (Antifibrinolytics).
Interaction-context constraints:	Interactions are primarily constrained by the drug's activity on the blood coagulation system, leading to increased risk of hemorrhage when co-administered with agents that affect hemostasis.

Resulting Interaction Structure

Official interaction statements:

• Co-administration with anticoagulants (such as Heparin or oral anticoagulants) is documented to increase the risk of hemorrhage.
• The risk of bleeding is similarly increased when combined with antiplatelet agents (including Aspirin) and certain non-steroidal anti-inflammatory drugs.
• Aminocaproic acid and similar antifibrinolytic agents are listed as inhibiting the therapeutic effect of Streptokinase on plasminogen activation.
• Specific herbal products that possess antiplatelet activity, such as Garlic and Ginger, are documented in regulatory summaries as posing an increased risk of bleeding.

Connection to the overall interaction profile:

The regulatory interaction profile for this medicine is strictly defined by the high risk of hemorrhage associated with its potent thrombolytic effect. Regulatory documents classify co-administration with other hemostasis-affecting substances as clinically significant or, in the case of prior exposure to the drug itself, a formal contraindication. This structure outlines prohibitions and constraints derived exclusively from official label text.

Streptokinase is an extracellular protein that acts as a plasminogen activator by an indirect, non-enzymatic mechanism.

Upon systemic administration, Streptokinase forms a high-affinity, stoichiometric 1:1 molecular complex with the circulating zymogen plasminogen. This interaction induces a conformational change in the plasminogen moiety, resulting in the exposure of an active catalytic site within the complex. This newly formed streptokinase–plasminogen complex functions as an allosteric enzyme that acts as an agonist for unbound substrate plasminogen molecules. The complex proteolytically cleaves the Arg561–Val562 peptide bond in circulating plasminogen, converting it into the active serine protease, plasmin. This conversion initiates a downstream cascade in the fibrinolytic system, where plasmin proceeds to hydrolyze fibrin polymers within a formed mesh. This proteolytic degradation of the fibrin matrix yields soluble fibrin degradation products, modulating the system-level integrity of the fibrin clot and altering blood flow dynamics.

Streptokinase is a prescription medication administered exclusively by parenteral infusion under continuous medical supervision, typically in a hospital setting. It is supplied as a lyophilized powder for injection and requires reconstitution with an appropriate diluent, such as Sodium Chloride or Dextrose Injection, immediately prior to use. Official instructions state that the vial must be gently rolled or tilted to dissolve the powder, and shaking must be avoided to prevent foaming.

Official Dosing Regimens

Indication Context	Administration Pattern	Duration
Acute Myocardial Infarction	Single, fixed dose of 1,500,000 International Units (IU) via intravenous infusion.	Infused over 60 minutes.
Pulmonary Embolism (PE)	250,000 IU loading dose over 30 minutes, followed by a continuous maintenance dose of 100,000 IU/hour via an infusion pump.	24 hours (extended up to 72 hours for concurrent DVT).
Deep Vein Thrombosis (DVT)	250,000 IU loading dose over 30 minutes, followed by 100,000 IU/hour continuous infusion.	72 hours.
Occluded Cannulae	250,000 IU is locally instilled into each occluded limb of the cannula.	Limbs are clamped for 2 hours after instillation.

Administration for systemic conditions is strictly short-term, restricted to a matter of hours or days following the acute event. Because of the risk of developing anti-streptokinase antibodies, re-administration of the medicine is generally avoided between 5 days and 12 months after the initial dose. Specific dosing guidance for pediatric patients is not available in the official prescribing information.

The research base for Streptokinase focuses on its clinical evaluation for the management of acute blood clots across three main areas. This evidence is primarily derived from studies conducted in the late 1980s and early 1990s.

Acute Myocardial Infarction (AMI / STEMI)

Pivotal, large-scale Randomized Controlled Trials (RCTs) examined the drug's role in STEMI management, tracking patient survival and blood flow measurements (reperfusion rates). These trials reported measurements of survival rates that differed when evaluating the drug against placebo controls. The findings reflect the standards of care used when the research was conducted, and comparative evidence against modern reperfusion methods is limited.

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

For DVT, studies focused on whether clot dissolution (lysis) was achieved and monitored the long-term risk of post-thrombotic syndrome (PTS). Studies reported patterns of lysis measurements observed against standard thinners, but also noted a higher rate of specific adverse findings was associated with the treated group. For PE, trials monitored physiological strain and tracked patient survival; findings were mixed regarding overall differences in survival in unselected patients, though some studies reported observed shifts in hemodynamic measurements in patients with massive PE.

Evidence Gaps and Limitations

The original evidence is older, meaning current comparative research against modern standards of care is limited. The evidence quality varies across studies, with many key trials having short-term follow-up periods. Data for certain groups, such as older adults or those with comorbidities, remain insufficient, and long-term effects beyond one year are not fully established.

Key Studies & References

1. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.
2. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).

Common questions about Streptokinase (FAQ)

Q: How does Streptokinase differ from other 'clot-busting' medicines?

According to the official product information, Streptokinase is differentiated from some other clot-busting medicines by its mechanism. It is classified as a non-enzymatic plasminogen activator, meaning it indirectly initiates the process of clot dissolution. Regulatory documents note that because of these differences, it is typically not recommended for conditions like acute ischemic stroke, for which other specific thrombolytic agents are approved.

Q: Does age affect who can or cannot receive treatment with Streptokinase?

Official information addresses eligibility based on age groups. It states that the safety and efficacy of the drug have not been established in pediatric patients (children). Furthermore, in older adults, official documents note a potentially increased risk of cerebral hemorrhage (bleeding in the brain). The information highlights the need for caution in this population.

Q: Is Streptokinase a type of enzyme?

Streptokinase is classified as a potent thrombolytic agent and a plasminogen activator. While it is prepared from a bacterial source, its mechanism is described as indirect and non-enzymatic. It functions by forming a complex that activates the body's natural clot-dissolving substance, plasminogen, which is the true enzyme.

Q: What kind of follow-up monitoring is usually described after using Streptokinase?

Post-treatment guidance indicates that patients are monitored for signs of successful clot dissolution and stabilization, such as relief of symptoms or changes in heart rhythm. Following the infusion, monitoring and maintenance of anticoagulation therapy (using blood thinners) are initiated as a necessary part of the overall treatment plan.

Q: Can Streptokinase interact with anesthetics used in dental procedures?

Official information advises that invasive procedures, including injections, should generally be avoided during therapy due to the drug's high risk of causing bleeding. Official patient advisories recommend informing all healthcare providers, including dentists and surgeons, about the use of this medication to manage potential bleeding risks.

Q: Does Streptokinase cause any long-term effects?

Studies cited in regulatory summaries primarily focus on short-term outcomes. The research evidence base includes a data gap, noting that long-term effects and overall safety beyond one year are generally not fully established in major clinical trials for the drug.

Q: Can Streptokinase be used for conditions other than heart attacks and deep vein thrombosis?

Yes, official indications for use include more conditions than the most common ones. In addition to heart attack (myocardial infarction) and deep vein thrombosis (DVT), the drug is also indicated for treating acute arterial thrombosis or embolism and for clearing occluded arteriovenous cannulae.

Q: Do food or supplements impact how Streptokinase works?

Official interaction statements do not generally address food. However, they specifically document certain herbal products (such as Garlic and Ginger) that have antiplatelet activity. Co-administration with these specific supplements is noted as potentially increasing the risk of bleeding.

Q: Is Streptokinase considered a high-risk medication?

Yes, the medication is categorized in clinical safety protocols as a High Alert medication. This is due to the potential for serious harm if administered incorrectly. Its label includes a Boxed Warning that details the risk of major bleeding complications.

Q: What is the connection between Streptokinase and allergic reactions?

The drug is a purified bacterial protein, which makes it highly antigenic (recognized by the immune system). The body may develop anti-streptokinase antibodies in response. The presence of these antibodies can lead to allergic reactions, including severe anaphylaxis, and is a factor in the risk of re-administration.

Q: How does the body get rid of Streptokinase?

Pharmacokinetic data describes that the drug and the activator complex it forms are removed from the body through distinct elimination pathways. This process involves specific plasma half-lives, which reflect the time the substance or its active complex remains in the bloodstream.

Q: Is the reaction time of Streptokinase the same for all types of clots?

The required duration of infusion and treatment varies based on the condition being treated. For example, a heart attack may require a single 60-minute infusion, while deep vein thrombosis (DVT) may require a continuous infusion for up to 72 hours. These different durations reflect variances in the administered treatment time for different conditions.

Q: What are the general expectations about recovery after receiving Streptokinase?

The initial expectation is for close monitoring to assess for successful clot dissolution and patient stabilization. Following the acute treatment phase, patients are usually transitioned to anticoagulation therapy as a necessary part of the long-term management plan.

Q: Does the official information mention any risks for people with high blood pressure who use Streptokinase?

Yes, official warnings include risks related to blood pressure. Severe, uncontrolled hypertension (high blood pressure, often defined as systolic pressure over 180 mmHg) is explicitly listed as an absolute contraindication or a major risk factor. This is due to a substantially increased risk of hemorrhagic stroke.

Q: What is the descriptive role of Streptokinase in an emergency room setting?

The medication is reserved for acute, life-threatening scenarios, underscoring its role in rapid intervention. This includes treatment for massive pulmonary embolism and severe heart attack (STEMI), particularly when more advanced reperfusion treatments are not immediately available.

Q: What common side effects are considered mild or temporary?

Regulatory documents describe certain adverse reactions as generally mild or temporary. These typically include fever, chills, flushing, rash, and minor oozing or bruising at puncture sites (ecchymosis). These effects are described as generally mild or temporary and are subject to monitoring during and after administration.

Q: Are there any major diet changes mentioned in official guidance for people receiving Streptokinase?

Official prescribing information focuses on interactions with other medicines and specific herbal products that increase bleeding risk. Major, general dietary restrictions or overall diet changes are not typically addressed or mentioned in the regulatory warnings for this drug.

Q: What are the criteria that doctors use to decide if Streptokinase is appropriate?

The decision is based on two primary criteria derived from official guidance. First, the patient must have an objectively diagnosed thrombotic event that is indicated for the drug. Second, the patient must not have any absolute contraindications, such as active internal bleeding or a recent stroke.

Q: Do the official documents describe a maximum number of times Streptokinase can be used?

Official documents strongly advise against re-administration to a patient who has received the drug in the past. This is because the body develops neutralizing anti-streptokinase antibodies, which can persist for a long period, compromising the drug's efficacy and dramatically increasing the risk of a severe allergic reaction.

Official Storage and Disposal Requirements

Regulatory documents outline specific environmental controls for Streptokinase (lyophilized powder for injection). The powder must be stored in a refrigerator, maintaining a temperature range of 2 C to 8 C (36 F to 46 F), and must explicitly not be frozen.

Condition	Regulatory Requirement
Unreconstituted Powder	Store refrigerated (2 C to 8 C). Do not freeze.
Post-Reconstitution Stability	Use immediately; stability is limited to 8 hours when refrigerated.
Disposal	Discard any unused reconstituted solution and do not discharge the product into drains or sewer systems.

Because the vial contains no preservatives, the solution should be prepared immediately before use. After reconstitution, the product should be discarded if not used within eight hours. Disposal of the unused product and containers must be executed according to local regulatory guidelines, ensuring it does not enter public wastewater systems.